Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Screening and Identification of Human Urate Transporter hURAT1 MicroRNA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01973088
Recruitment Status : Unknown
Verified September 2013 by Qian-wei Li, Southwest Hospital, China.
Recruitment status was:  Active, not recruiting
First Posted : October 31, 2013
Last Update Posted : December 10, 2013
Sponsor:
Information provided by (Responsible Party):
Qian-wei Li, Southwest Hospital, China

Brief Summary:
This study intends to use in patients with renal tissue and blood samples, screening and identification of renal tissue hURAT1 regulating the expression of micro-RNA, for further study of uric acid stone formation mechanism and the occurrence of clinical preventive uric acid stones provide new clues and new intervention targets.

Condition or disease
Urinary Calculi

Layout table for study information
Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : November 2013
Estimated Primary Completion Date : June 2015

Group/Cohort
non-urate calculus
non-calculus
urate calculus



Primary Outcome Measures :
  1. micro-RNA [ Time Frame: 6 months ]
    microRNA microarray:the micro-RNA of kidney tissue


Secondary Outcome Measures :
  1. Urine [ Time Frame: 24 hours ]
    Urine Analyzer:Urine color, transparency, pH, erythrocytes, leukocytes, epithelial cells, casts, protein, specific gravity, and qualitative urine

  2. 24h urine quantitative analysis [ Time Frame: 96 hours ]
    Urine Analyzer:Urine, sodium, potassium, calcium, magnesium, ammonium, phosphate, sulfate, uric acid, oxalate, citrate, creatinine

  3. Blood biochemistry [ Time Frame: 24 hours ]
    Blood biochemical analyzer:Sodium, potassium, chloride, calcium, phosphorus, magnesium, bicarbonate, uric acid, creatinine

  4. Stone analysis [ Time Frame: 3 weeks ]
    Infrared Spectroscopy:Calcium oxalate monohydrate , carbonated apatite, calcium oxalate dihydrate ,anhydrous uric acid, urine ammonium,magnesium ammonium phosphate

  5. hURAT1 transporter protein [ Time Frame: 6 months ]
    WESTERN BLOT、RT-qPCR:hURAT1 transporter protein of kidney tissue



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Experiment are divided into uric acid stones group (A), non-uric acid stones group (B), control group (C), A, C recruited 30 patients each group, B group recruited 20 patients.
Criteria

Inclusion Criteria:

A、B group were enrolled standards: ① aged 18-65 years old; ② comply with percutaneous nephrolithotomy lithotripsy indications for surgery; ③ ECT tips ipsilateral normal or mildly impaired renal function.

Group C patients were enrolled standards: ① aged 18-65 years old; ② normal renal function, not associated with urinary calculi in patients; ③ cancer patients met radical nephrectomy indications for surgery; ④ emergency trauma patients suffering from kidney resection surgical indications.

Exclusion Criteria:

  • aged <18 years or> 65 years; ② neurological disease or cognitive dysfunction; ③ can not be corrected or uncorrected coagulopathy; ④ associated with diabetes, hypertension and other metabolic diseases; ⑤ accompanied by tuberculosis, hepatitis, HIV and other infectious diseases; ⑥ poor tolerance to anesthesia and surgery, such as: severe cardiopulmonary disease, coagulation disorders, etc.; ⑦ ultrasound, renal imaging examination revealed renal cortex was significantly thinner (renal cortical thickness <1.5cm), structural variation; ⑧ with severe systemic or urinary tract infection; ⑨ ECT tips ipsilateral renal function is severely impaired or solitary kidney.

Layout table for additonal information
Responsible Party: Qian-wei Li, Southwest Hospital, China
ClinicalTrials.gov Identifier: NCT01973088     History of Changes
Other Study ID Numbers: Southwest Hospital,TMMU
First Posted: October 31, 2013    Key Record Dates
Last Update Posted: December 10, 2013
Last Verified: September 2013

Additional relevant MeSH terms:
Layout table for MeSH terms
Calculi
Urinary Calculi
Pathological Conditions, Anatomical
Urolithiasis
Urologic Diseases